On September 18, 2017, the 14th Scientist Forum co-sponsored by China Future Research Association, China High-tech Industrialization Research Association, China Technology Market Association, and Discovery Magazine was held in Beijing Convention Center. The theme of this forum It is "Science and Technology Innovation Leads Big Science". More than 800 scientists, technology managers, technology professionals and entrepreneurs from various industries across the country attended the meeting.

Site of the 14th Scientist Forum (Picture 1)

Site of the 14th Scientist Forum (Figure 2)

Technology is the foundation of a country's prosperity, and innovation is the soul of national progress. At present, a new round of scientific and technological revolution in the world plays an important role in social development, and the country has regarded technological innovation as the core of its innovation-driven development strategy.

In order to encourage the enthusiasm and creativity of the majority of scientific and technological innovation and entrepreneurial workers, promote the development and application of my country's science and technology, and further give play to the role of science and technology in promoting social and economic development, this forum of scientists will also contribute to the development of China's science and technology. Institutions and individuals issued honorary certificates to encourage participating companies to make remarkable achievements in promoting social and economic development and strengthening scientific and technological innovation methods. Shenzhen Yishi Kangning Biotechnology Co., Ltd. was fortunate to be invited to participate in this conference and explain the clinical trial research report of ACTLTM targeted anti-tumor cell immune technology to treat cancer. With outstanding contributions to biotechnology innovation, it was awarded the "Discovery· "2017 Advanced Unit of Technological Innovation" and "Discovery 2017 Advanced Individual of Technological Innovation".

Yishikangning focuses on the scientific and standardized development of ACTLTM targeted anti-tumor cell immune technology and its product group. With innovation as the core development direction, the company has successively cooperated with Cleveland Medical Center Cancer Institute, Stanford University Cancer Institute, University of Texas MD Anderson Cancer Center, Rockefeller Cancer Institute, Peking University Shenzhen Hospital , Sun Yat-sen University Affiliated Tumor Hospital, Jiangsu Provincial People's Hospital and other Jiangsu hospitals have reached strategic cooperation, forming a unique concept in the field of science.

This award also fully demonstrated the country's affirmation of ISKCON's biological science research and development results. Technology creates life, Corning leads the future! ISKCON will also work hard to actively promote the development of innovative enterprises in China, and strive unremittingly for the cause of national health!On September 18, 2017, the 14th Scientist Forum co-sponsored by China Future Research Association, China High-tech Industrialization Research Association, China Technology Market Association, and Discovery Magazine was held in Beijing Convention Center. The theme of this forum It is "Science and Technology Innovation Leads Big Science". More than 800 scientists, technology managers, technology professionals and entrepreneurs from various industries across the country attended the meeting.

Site of the 14th Scientist Forum (Picture 1)

Site of the 14th Scientist Forum (Figure 2)

Technology is the foundation of a country's prosperity, and innovation is the soul of national progress. At present, a new round of scientific and technological revolution in the world plays an important role in social development, and the country has regarded technological innovation as the core of its innovation-driven development strategy.

In order to encourage the enthusiasm and creativity of the majority of scientific and technological innovation and entrepreneurial workers, promote the development and application of my country's science and technology, and further give play to the role of science and technology in promoting social and economic development, this forum of scientists will also contribute to the development of China's science and technology. Institutions and individuals issued honorary certificates to encourage participating companies to make remarkable achievements in promoting social and economic development and strengthening scientific and technological innovation methods. Shenzhen Yishi Kangning Biotechnology Co., Ltd. was fortunate to be invited to participate in this conference and explain the clinical trial research report of ACTLTM targeted anti-tumor cell immune technology to treat cancer. With outstanding contributions to biotechnology innovation, it was awarded the "Discovery· "2017 Advanced Unit of Technological Innovation" and "Discovery 2017 Advanced Individual of Technological Innovation".

Yishikangning focuses on the scientific and standardized development of ACTLTM targeted anti-tumor cell immune technology and its product group. With innovation as the core development direction, the company has successively cooperated with Cleveland Medical Center Cancer Institute, Stanford University Cancer Institute, University of Texas MD Anderson Cancer Center, Rockefeller Cancer Institute, Peking University Shenzhen Hospital , Sun Yat-sen University Affiliated Tumor Hospital, Jiangsu Provincial People's Hospital and other Jiangsu hospitals have reached strategic cooperation, forming a unique concept in the field of science.

This award also fully demonstrated the country's affirmation of ISKCON's biological science research and development results. Technology creates life, Corning leads the future! ISKCON will also work hard to actively promote the development of innovative enterprises in China, and strive unremittingly for the cause of national health!